Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.

Atypical Pneumonia

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Exploring glucocorticoid receptor signalling in lymphangioleiomyomatosis.

ERJ open research·2026

Same author

Clinical Effectiveness and Safety of Multimodal Prehabilitation in Colorectal Cancer Surgery-A Narrative State-of-the-Art Review of Research and Clinical Trials.

Journal of clinical medicine·2026

Same author

Long-term outcomes of sirolimus therapy in sporadic and tuberous sclerosis complex-associated lymphangioleiomyomatosis: a retrospective cohort study.

Polish archives of internal medicine·2026

Same author

Kaposiform lymphangiomatosis-the effects of long-term treatment with sirolimus: case series study and review of the literature.

Frontiers in medicine·2026

Same author

Cladribine treatment of a young patient with isolated progressive pulmonary Langerhans histiocytosis complicated by invasive aspergillosis.

Polish archives of internal medicine·2026

Same author

Access to lymphangioleiomyomatosis care across Europe: an ERN-LUNG survey of clinical practice, and the case for a European registry and trial network.

ERJ open research·2026

Search research articles

Related Experiment Videos

[Organizing pneumonia--clarithromycin treatment].

Elzbieta Radzikowska¹, Elzbieta Wiatr, Dariusz Gawryluk

¹III Klinika Chorób Płuc Instytutu Gruźlicy i Chorób Płuc w Warszawie Kierownik. e.radzikowska@igichp.edu.pl

Pneumonologia I Alergologia Polska

|November 13, 2008

Summary

Organizing pneumonia (OP) can be effectively treated with clarithromycin, offering a viable alternative to steroids, especially for patients at high risk of corticosteroid side effects. This study shows promising results for clarithromycin in managing OP symptoms and radiological findings.

Related Experiment Videos

Area of Science:

Pulmonology
Infectious Diseases
Pharmacology

Context:

Organizing pneumonia (OP) is a rare idiopathic or secondary lung disease.
Steroids are the conventional treatment, but alternative therapies are sought.
OP presents with diverse symptoms and characteristic radiological findings.

Purpose:

To evaluate the efficacy of clarithromycin (CLA) in treating organizing pneumonia (OP).
To assess clarithromycin as an alternative treatment for OP, particularly when corticotherapy is contraindicated or associated with high risk.

Summary:

A study of 12 patients (9 women, 3 men) with OP treated with clarithromycin (0.5 g b.i.d).
75% of patients achieved complete clinical and radiological remission within 3-4 months.
No adverse reactions or relapses were observed during a mean follow-up of 42 months.

Impact:

Clarithromycin demonstrates significant efficacy in treating organizing pneumonia.
It presents a valuable alternative therapeutic option, especially for patients with contraindications or high risk of adverse events from corticosteroids.
This finding supports the use of antibiotics in managing certain interstitial lung diseases.